Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced ...

Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...

Sierra Boggess opens the Princeton Festival on June 5 and Time for Three performs June 18.

The Delhi High Court has stayed trial court proceedings against Bina Modi and Lalit Bhasin, who were summoned in an assault ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...

J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.

In a groundbreaking milestone for Bangladesh’s fintech industry, aamarPay, a leading payment system operator (PSO), has ...

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H ...

US FDA approves Novartis Cosentyx for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa: Basel Monday, March 16, 2026, 14:00 Hrs [IST] Novartis announc ...